Replies to post #14 on Claritus Pharmaceuticals Inc. (CLAZF)

[RadMan66]

Thar she bloooooooows. :)

[RadMan66]

[RadMan66]

WOW.. Not one NR but 2 in one day.. Gotta love this puppy...

First one I can't post here cuz it's not for the US market but one can visit their website and check it out but the below doesn't have a U.S. cautionary note so one must assume it's OK to pass on good news.. :)

Webcast???.. One may want to ask themselves why do a webcast if the results are not good ones..

Kalytera to Announce Phase 2a Clinical Study Results Investigating CBD for the Treatment of Acute Graft versus Host Disease

By Kalytera February 16, 2017GvHD, Press Release

Kalytera to host conference call and webcast on Thursday, February 23, 2017 at 12:00 PM ET

Kalytera Therapeutics, Inc. (TSXV: KALY) (“Kalytera”) will announce the results of a Phase 2a study investigating the safety and efficacy of cannabidiol (“CBD”) for the treatment of acute (Grades 3-4) Graft versus Host Disease (“GvHD”) on Wednesday, February 22, 2017.

A conference call and webcast will be held on Thursday, February 23, 2017 at 12:00 PM ET to discuss the study results.

The Phase 2a study was conducted by Talent Biotechs, Ltd. (“Talent”), an Israeli-based company evaluating the use of CBD to prevent and treat GvHD, that has been newly acquired by Kalytera.

GvHD is a multisystem disorder that is a common, life-threatening complication of hematopoietic stem cell transplant (“HCT”) procedures.

HCT is a lifesaving procedure for many diseases of the blood and bone marrow including leukemia, Hodgkin and Non-Hodgkin lymphoma, and multiple myeloma. GvHD occurs when the transplanted donor cells attack the patient’s organs, including the skin, gastrointestinal tract, liver, lungs, and eyes. GvHD is associated with acute and chronic illness, infections, disability, reduced quality of life, and death.

The Phase 2a treatment study enrolled ten patients with acute GvHD, including five patients with Grade 3 GvHD and five patients with Grade 4 GvHD. All ten patients were steroid refractory, meaning that they had not responded to previously administered standard of care steroid treatment. Patients were administered daily doses of CBD for up to three months, alongside standard of care therapy.

Conference Call and Webcast Information
Date:Thursday, February 23, 2017
Time: 12:00 PM ET

Conference Call: http://dpregister.com/10101838 (Register to receive dial-in instructions)

Webcast: http://services.choruscall.com/links/kaly170223.html (Allow at least ten minutes to access the site before the webcast begins)

The conference call and webcast will be available for replay on the Kalytera website.